FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BLOCK, K.
Right arrow Articles by TAYLOR, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BLOCK, K.
Right arrow Articles by TAYLOR, H. S.
(The FASEB Journal. 2000;14:1101-1108.)
© 2000 FASEB

In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing müllerian system

KAREN BLOCK*, ANDREW KARDANA*, PETER IGARASHI{dagger} and HUGH S. TAYLOR*1

* Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut, 06520, USA; and
{dagger} Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, 06520 USA

1Correspondence: Department of Obstetrics and Gynecology, Yale University School of Medicine, 333 Cedar St., New Haven, Connecticut 06520 USA. E-mail: hugh.taylor{at}yale.edu


   ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Diethylstilbestrol (DES) was widely used to treat pregnant women through 1971. The reproductive tracts of their female offspring exposed to DES in utero are characterized by anatomic abnormalities. Here we show that DES administered to mice in utero produces changes in the expression pattern of several Hox genes that are involved in patterning of the reproductive tract. DES produces posterior shifts in Hox gene expression and homeotic anterior transformations of the reproductive tract. In human uterine or cervical cell cultures, DES induces HOXA9 or HOXA10 gene expression, respectively, to levels approximately twofold that induced by estradiol. The DES-induced expression is not inhibited by cyclohexamide. Estrogens are novel morphogens that directly regulate the expression pattern of posterior Hox genes in a manner analogous to retinoic acid regulation of anterior Hox genes. Alterations in HOX gene expression are a molecular mechanism by which DES affects reproductive tract development. Changes in Hox gene expression are a potential marker for the effects of in utero drug use that may become apparent only at late stages of development.—Block, K., Kardana, A., Igarashi, P., Taylor, H. S. In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing müllerian system.


Key Words: genes • homeobox • teratogens • fetal development • estrogens


   INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
THE NONSTEROIDAL ESTROGEN diethylstilbestrol (DES) was once widely used in an attempt to treat women considered at risk for adverse pregnancy outcomes. It is estimated that 2 to 3 million pregnant women were treated with the drug (1) . However, in 1971 DES was banned from being used during pregnancy after the demonstration of an increase in adenocarcinoma of the vagina in young women exposed to the drug in utero (2) . Subsequently, it has been demonstrated that women exposed in utero have a high incidence of anatomic abnormalities of the genital tract that adversely affect their reproductive capacity. Various estrogens have been shown to alter stromal epithelial interactions and result in anomalies of the reproductive tract, but the molecular mechanisms by which estrogens alter the development of the müllerian tract are unknown (3 4 5) .

We have previously demonstrated that Hox genes are involved in determining the developmental identity of segments of the reproductive tract (6) . The nested expression of Hox genes impart positional identity along multiple developing axis, representing a universal molecular mechanism by which spatial distinctions can be encoded: the linear arrangement of these genes on a chromosome is paralleled by their temporal and spatial expression patterns. Ectopic expression of HOX genes can cause homeotic transformation in which body structures are duplicated in abnormal positions or replaced along the anterior-posterior body axis. The developing müllerian system represents such an axis. Hoxa9, Hoxa10, Hoxa11, and Hoxa13 are expressed along the axis of the previously undifferentiated paramesonephric duct in segments that give rise to oviducts, uterus, uterine cervix, and upper vagina, respectively. Targeted mutation of several posterior HOX genes that are paralogs of the Drosophila abdominal B (AbdB) gene results in defects in the female reproductive tract of mice, suggesting that alterations in HOX gene expression could be a basis for DES-related anomalies (7 8 9 10 11 12) . This Hox axis found in the mouse reproductive tract is conserved in the human reproductive tract as evidenced by an equivalent expression pattern of human HOX genes (6) . HOX gene expression in the developing reproductive tract of the mouse may be a suitable model to evaluate the effects of potentially harmful drugs, such as DES, on human development.

HOX genes expressed in the developing reproductive tract demonstrate persistent adult expression (6) . Insults to the developing müllerian organs in utero may be reflected in the adult pattern of HOX gene expression. We have recently shown that HOXA10 and HOXA11 expression is directly regulated by 17ß-estradiol in humans (13 , 14) . In this study, we ask whether exposure in utero to the nonsteroidal estrogen DES alters the expression of these HOX genes in the developing reproductive tract, providing a molecular mechanism by which DES produces congenital anomalies.


   MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Animals
Outbred CD-1 mice were bred to male mice of the same strain. Detection of a vaginal plug was considered day 0 of pregnancy. Pregnant mice were treated with intraperitoneal injection of DES (10 µg/kg of maternal body weight) on days 9–16, inclusive, of gestation. DES was dissolved in sesame oil and ethanol. Controls received oil/ETOH alone. Experiments were conducted in accordance with the Yale University Animal Care Committee guidelines.

Probe preparation
Plasmids used for probe preparation were a generous gift from E. Boncinelli. pGEM plasmids containing sequence from the 3' untranslated region of human HOXA9, HOXA10, HOXA11, and HOXA13 were linearized with EcoRI or HindIII (New England Biolabs, Beverly, Mass.), ethanol precipitated, and individually used as a template for generation of riboprobes. Radiolabeled RNA probes were generated by in vitro transcription using the Promega Riboprobe Kit (Madison, Wis.). Sense and antisense probes were generated using the appropriate RNA polymerase (T7 or SP6) and labeled with alpha-[33P] or [32P] UTP (Amersham, Arlington Heights, Ill.).

Northern blot analysis
Tissues or cultured cells were homogenized in 4 M guanidinium thiocyanate, 25 mM sodium citrate (pH 7.0), 0.5% sarkosyl, and 0.1 M 2- mercaptoethanol. Total RNA was size-fractionated on a 1% agarose-0.66 M formaldehyde gel, blotted to nitrocellulose, and hybridized with a [32P]-labeled riboprobe prepared as described above. Hybridization was performed overnight at 60°C in 50% formamide, 1x SSC, 5x Denhardt’s reagent, 0.2% tRNA, and [32P]-labeled riboprobe at 2 x 106 cpm/ml. The filter was washed twice at 68°C for 30 min in 0.1x SSC and 0.1% sodium dodecyl sulfate. Kodak (Rochester, N.Y.) X-Omat AR film was exposed overnight at -70°C.

In situ hybridization
In situ hybridization was performed with both sense and antisense [33P]-labeled riboprobes. Tissue was fixed in 4% paraformaldehyde, cryoprotected in 30% sucrose, and embedded in OCT compound (Miles, Elkhart, Ind.). Ten micrometer frozen sections were obtained and mounted on Vectabond-coated slides (Vector Laboratories, Burlingame, Calif.). Prior to use, sections were treated with 0.2 M HCl, Pronase (0.16 mg/ml), and 0.026 M acetic anhydride, then dehydrated. Tissue sections were hybridized overnight with 3 x 106 cpm of each probe in 0.25 M NaCl, 0.01 M Tris-HCl (pH7.5), 0.01 M NaP04 (pH 6.8), 5 mM EDTA, Ficoll 400 (0.02%), polyvinylpyrolidone (0.02%), bovine serum albumin (BSA) fraction V (0.02%), 50% formamide, 12.5% dextran sulfate, yeast tRNA (1.25 mg/ml), and 10 mM DTT. Hybridization was performed in a humidified chamber for 16 h at 50°C. Slides were treated with Rnase A at 37°C and then washed 16 h in 0.25 M NaCl, 0.01 M Tris-Cl (pH 7.5), 0.01 M NaP04 (pH 6.8), 5 mM EDTA, Ficoll 400 (0.02%), polyvinylpyrolidone (0.02%), BSA fraction V (0.02%), and 50% formamide. Slides were dehydrated and dried, and autoradiographs were obtained before being dipped in Ilford K5D (Mobberley, U.K.) emulsion. Exposure was carried out at 4°C for 7 to 12 days and slides were developed with Kodak D-19. Slides were counterstained with hematoxylin and eosin. Representative darkfield and brightfield photomicrographs were taken at 20x and 100x magnification respectively, on an Olympus (Lake Success, N.Y.) microscope with Kodak Ectachrome film.

Cell culture
Ishikawa and SKOV3 cells were maintained in phenol red-free Eagle’s minimum essential medium containing 10% (v/v) charcoal stripped fetal bovine serum and supplemented with penicillin (100 µg/ml), glutamine (2 mM), and sodium pyruvate (1 mM). HeLa cells were maintained in McCoy’s media modified as above. Confluent monolayers were maintained in serum-free media for 24 h and subsequently treated with 17ß-estradiol (5x10-8 M) or DES (5x10-8 M). HeLa cells were first transfected with a full-length human estrogen receptor expression construct (a gift of Richard Hochberg). A 25 cm2 cellular monolayer was transfected with 3 ml of a solution containing 16 µg/ml of pCMV5/hER and 40 µg/ml liposomes (lipofectamine) in phosphate-buffered saline. Cells were maintained in McCoy’s media an additional 24 h prior to treatment with 17ß-estradiol or DES. Estrogen and progesterone receptor status was verified in each cell line by enzyme-linked immunoassay according to the manufacturer’s instructions (Abbott, Wiesbaden, Germany).

Statistical analysis
The autoradiographic bands were quantified using a laser densitometer (Molecular Dynamics Inc., Sunnyvale, Calif.). Each band was normalized to the value obtained from the same lane hybridized to G3PDH. Data were analyzed using analysis of variance (ANOVA). Statistical significance was defined as P < 0.05.


   RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
DES alters Hox gene expression in the reproductive tract
To determine the effect of DES on Hox gene expression in the developing reproductive tract, 10 timed pregnant mice were treated with of DES at a concentration of 10 µg/kg of maternal body weight from days 9 to 16 of gestation, a protocol known to produce reproductive tract anomalies in females exposed in utero (15 , 16) . These alterations resemble those of affected women. Five DES-treated mice delivered litters of reduced size, whereas all five of the mice injected with a control delivered litters of normal size. At 2 wk of age, the female offspring were killed and reproductive tracts were dissected. DES-treated offspring exhibited typical reproductive tract anomalies. In situ hybridization was performed with 33P-labeled riboprobes complementary to each of the 3' untranslated regions of Hoxa9, Hoxa10, Hoxa11, and Hoxa13. Figure 1 shows darkfield photomicrographs of the results.



View larger version (77K):
[in this window]
[in a new window]
 
Figure 1. Localization of Hox gene expression in control mice. Representative in situ hybridization demonstrates Hoxa9, Hoxa10, Hoxa11, and Hoxa13 expression patterns in the normal mouse reproductive tract. A brightfield photomicrograph of section is shown for comparison. Note strong hybridization of Hoxa9 to the oviducts, Hoxa10 to the uterus, Hoxa11 to the posterior uterus, and Hoxa13 to the vagina. A sense control strand demonstrates absence of hybridization. The third column shows localization of Hox gene expression in mice exposed to DES in utero. The reproductive tracts appear abnormal as a consequence of DES exposure and demonstrate typical anomalies associated with DES exposure. The reproductive tracts show altered patterns of Hox gene expression. Hoxa9 is now expressed in the uterus instead of the oviduct. Hoxa10 expression is shifted to the posterior uterus. Hoxa11 is expressed at dramatically decreased levels in the uterus and Hoxa13 expression is unchanged.

The reproductive tracts of the mice exposed to DES are abnormally shaped reflecting the expected morphological changes found after DES exposure. Expression of Hoxa9 is localized to the oviducts in the control. In DES-exposed mice, Hoxa9 expression is found in a more caudal distribution. Hoxa9 is now expressed at appreciable levels in the uterus (Fig. 1) and expression is absent in the oviducts. Similarly, peak Hoxa10 expression is shifted to the base of the uterus from its normal expression pattern throughout the uterus. DES exposure in utero has resulted in the more caudal expression of Hoxa10. Hoxa10 expression is significantly decreased in its normal location of expression, the cranial aspect of the uterus (Fig. 1) . Hoxa11 expression is dramatically decreased throughout its normal range of expression in the uterus. Even at exposures of up to 12 days (shown here, 12 day exposure), Hoxall expression remains dramatically reduced. Hoxa13 is normally expressed in the vagina. DES exposure does little to alter Hoxa13 expression, as far as can be detected by in situ hybridization. Identical results were seen using tissue obtained from each of the experimental mice.

In summary, the results of the in situ hybridization show a posterior shift in Hoxa9 and Hoxa10 expression. A similar decrease in the anterior portion of the Hoxa11 expression domain is observed. Expression of the most posterior Hox gene, Hoxa13, is unaltered. DES exposure in utero leads to a persistent posterior shift in the Hox axis of the reproductive tract toward the expression domain of the most posteriorly expressed Hox gene, a13.

High-power brightfield views of tissue sections from DES-exposed mice after in situ hybridization confirm and localize the above results as shown in Fig. 2 . We previously defined normal cellular expression in the mouse for each of these genes (6) . After DES exposure, Hoxa9 expression is shifted to a tissue different from that where it is normally expressed, i.e., from the oviduct to the uterus. To identify which uterine cells expressed Hoxa9, high-power views were examined. A control sense probe lacks hybridization (Fig. 2a ). Both glands and stroma of the uteri obtained from DES-exposed mice abundantly expressed Hoxa9 (Fig. 2b ). Hoxa9 expression is absent from its normal location in the epithelium of the oviduct as demonstrated in Fig. 2c . High-power views of photomicrographs obtained after in situ hybridization with a Hoxa10 probe show Hoxa10 absent from both glands and stroma in the upper segment of the uterus but normally expressed in the caudal uterine segment (data not shown). Hoxa11 shows extremely low levels of expression in the uterus of DES-exposed mice, but the pattern of expression is unchanged from controls (data not shown). Hoxa13 expression is high in the vagina, its normal location, and is still found in the surface epithelium as previously demonstrated (Fig. 2d ).



View larger version (102K):
[in this window]
[in a new window]
 
Figure 2. Reproductive tract of DES-exposed mice shown at high power after in situ hybridization. a) A sense control Hoxa9 probe lacked any notable hybridization. b) Hoxa9 is not normally expressed in the uterus, but after DES exposure Hoxa9 is expressed in the both uterine glands and stroma. c) Hoxa9 is no longer expressed in the oviduct. d) Hoxa13 is expressed normally throughout the vaginal epithelium as previously demonstrated.

To quantify expression, Northern analysis was performed. Tissue was obtained separately from the oviduct, uterus, and vagina from both control mice and mice exposed to DES in utero. Five animals were used for each group. RNA was extracted, size-fractionated, and hybridized individually to 32P-labeled Hoxa9, Hoxa10, Hoxa11, and Hoxa13 riboprobes. Densitometry of the resultant autoradiographs was performed and Hox values were normalized to values obtained with G3PDH. Results are shown in Fig. 3 . Hoxa9 is normally expressed in the oviduct. Hoxa9 expression is dramatically decreased in the oviduct of DES-exposed mice. The expression of other Hox genes remains low in the oviduct of DES-treated mice, at levels similar to controls (Fig. 3 , first panel). Hoxa9 expression is dramatically increased in the uterus of DES-exposed mice when compared to controls (Fig. 3 , second panel), confirming and quantifying the results of the in situ hybridization. Hoxa10 levels are reduced in the uterus, reflecting the posterior shift in expression seen in the in situ hybridization and loss of expression from the uterine fundus. Hoxa11 levels are dramatically decreased.



View larger version (26K):
[in this window]
[in a new window]
 
Figure 3. Quantification of Hox gene expression in the mouse reproductive tract by Northern analysis. RNA was extracted from the oviducts, uterus, or vagina of control and DES-exposed mice and Northern blot analysis with densitometry performed. Results are normalized to G3PDH expression. DES exposure reduced the expression of Hoxa9 in the oviduct whereas expression of other Hox genes was unchanged. In the uterus, Hoxa9 expression was increased whereas Hoxa10 and Hoxa11 expression were decreased. Vaginal Hox gene expression was unchanged. Shown are the mean and standard error using tissue from five mice. *Statistically significant difference from levels in control mice by ANOVA.

In the vagina (Fig. 3 , third panel), Hox gene expression is only minimally altered. In controls Hoxa13 is the primary Hox gene expressed and remains so in DES-treated mice. Hoxa11 levels are increased, perhaps representing a posterior shift of Hoxall expression to the vagina, but not at a statistically significant level as detectable in this study.

DES alters Hox gene expression in human cell culture
To test for applicability of our mouse model to humans, uterine, cervical, or ovarian cell culture models were used. Hoxa9 is not normally expressed in the uterus of human or mice (6) . As demonstrated above, DES induces Hoxa9 expression in the uterus of mice in vivo. Expression of the Hox gene most affected in vivo in mice, Hoxa9, is altered by DES in human uterine cells in culture. Ishikawa cells, a well-differentiated endometrial adenocarcinoma cell line that we have previously demonstrated to express HOXA10 and HOXA11 in response to treatment with 17 ß-estradiol, (13 , 14) , were treated with DES. Cells were treated with inert vehicle (control), 17ß-estradiol, or DES, then RNA extracted with guanidinium thiocyanate/phenol, size fractured on a formaldehyde gel, transferred to a membrane, and hybridized with a 32P-labeled probe specific to the 3' untranslated region of HOXA9. Autoradiography and densitometry were performed and normalized in G3PDH. DES produced a fourfold increase in expression of HOXA9 as compared to control (Fig. 4 HOXA9 mRNA levels after DES treatment also differed from that of cells treated with 17 ß-estradiol. Cyclohexaminde pretreatment did not block the response, indicating DES likely directly regulates HOX gene expression.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 4. Hox gene expression in Ishikawa, HeLa and SKOV-3 cells in response to 17ß-estradiol or DES treatment. A) Ishikawa cells (a well-differentiated endometrial adenocarcinoma cell line) were demonstrated to be estrogen receptor positive and were used as a model of endometrium. HOXA9, which is expressed in the endometrium of DES-exposed mice by not control mice, was measured by Northern analysis and densitometry after exposure to either DES or estradiol. Expression increased approximately twofold when cells were treated with estradiol. Treatment with DES produces a fourfold increase in HOXA9 expression. Error bars are SE; each is statistically different from the other at P < 0.05. B) HELA cells, a cervical carcinoma cell line, were used as a model of the cervix. HOXA10 is expressed in the cervix of DES-exposed mice but not controls. HOXA10 expression is shown not to exceed control levels with estradiol treatment, but to increase dramatically with DES treatment. C) SKOV-3 cells were used as a model of ovary. This tissue is not of müllerian origin and does not usually express HOXA9, HOXA10, HOXA11, or HOXA13 at high levels. Nor does DES exposure in vivo induce expression. Similarly, treatment with DES does not induce HOX gene expression is SKOV-3 cells.

HeLa cells, a cervical carcinoma cell line, were used as a model for the cervix. As demonstrated above, HOXA10 is expressed in the cervix of DES-exposed mice but not at significant levels in controls. HOXA10 expression does not exceed control levels when HeLa cells are treated with 17ß-estradiol (Fig. 4B ). Treatment of these cells with DES expression dramatically increases HOXA10 expression.

SKOV-3 cells were used as a model of ovary. This tissue is not of müllerian origin and does not normally express HOXA9, HOXA10, HOXA11, or HOXA13 at high levels. Neither 17ß-estradiol nor DES induces HOX gene expression in this cell line. Figure 4C demonstrates a lack of change in HOXA10 expression in response to treatment with these estrogens. Similarly, there was no change in expression of HOXA9, HOXA11 or HOXA13 (not shown).

DES produces an increased expression of HOXA9 in a uterine endometrial cell line and an increased expression of HOXA10 in a cervical cell line. These effects mimic the posterior shift in Hox gene expression seen in tissues that correspond to these cell lines. A cell line of reproductive tract origin but not of müllerian origin does not show these effects.


   DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
DES-induced homeotic transformation of the reproductive tract
Hox genes are highly evolutionarily conserved and act as the principal regulators of tissue identity during development. They play an essential role in assigning tissue identity to cells along the multiple anterior-posterior axis of the embryo (17 , 18) . The reproductive tract represents such an axis; differential Hox gene expression in segments of the undifferentiated paramesonephric duct leads to development of distinct reproductive organs (6) . Alterations of Hox gene expression of the type demonstrated here can be expected to lead to anomalies in the tissues that depend on their expression for proper development signals. Typically, the more posterior Hox genes are phenotypically dominant; they suppress the expression and function of the more anterior Hox genes, a property termed posterior prevalence (17) . The alterations in Hox gene expression patterns described above represent a posterior shift from the normal pattern. DES induces a posterior shift in Hoxa10 expression such that much of the uterus expresses less Hoxa10. DES also decreases Hoxa11 expression throughout the uterus. Hoxa10 and Hoxa11 expression in the uterus likely normally represses Hoxa9 expression. Decreased levels of expression of Hoxa10 and Hoxa11 may now allow for the increased Hoxa9 expression levels that are demonstrated after DES exposure.

The decreased Hoxa9 levels may lead to reduced or altered differentiation in the pathway leading to the development of the oviduct. This could account for the abnormal oviducts seen in mice after DES exposure and the ‘withered’ fallopian tubes seen in women who were exposed to DES in utero (19) . Complete absence of the tubes may not occur because of the redundancy provided by Hox genes from the Hox B, C, and D clusters.

Similarly, the decreased Hoxa10 and Hoxa11 and increased Hoxa9 expression in the uterus may cause the uterus to develop along a pathway consistent with the tissue normally directed to develop by Hoxa9: the oviduct. Accordingly, the classic T-shaped uterus, seen in up to 70% of women exposed to DES in utero, may represent an oviduct like phenotype. The uterus is narrowed and branches into two tube-like structures, resembling the shape of the letter T rather than a pear-shaped cavity. This shape may represent transformation into an oviduct-like structure. Again, complete transformation to an oviduct may be prevented by the redundancy provided by the other Hox clusters.

These alterations in Hox gene expression represent a posterior shift from the normal pattern. The presence of tissue in more posterior locations is common in women exposed to DES. For example, these women develop vaginal adenosis, which is the development of glandular tissue (normally found in the cervix or uterus) in the vagina. Changes in the reproductive tract seen after DES exposure may represent homeotic transformation typical of that seen with mutation and loss of function of homeotic genes in other species. Typically, Hox gene mutations result in posterior structures taking on the appearance of the next most anterior structure. The changes seen in reproductive anatomy in women after DES exposure are typical of this type of anterior transformation and correlate well with the changes in HOX expression reported above. DES-induced posterior shifts in HOX gene expression lead to anterior transformations of the reproductive tract. These molecular changes may explain the anatomic defects seen in women exposed to DES.

Alterations of Hox gene expressions are a molecular mechanism by which DES-related congenital malformations may occur.

Estrogen regulation of the Hox gene axis of the reproductive tract
Few regulators of the spatial expression patterns of Hox genes are known (18 , 20 , 21) ; estrogens are novel morphogens capable of segmental regulation of Hox genes during development. Sex steroids likely influence the expression levels of, and establish an axis of the posterior Hox genes, analogous to the role of retinoic acid in establishing expression patterns of the anterior Hox genes (22 23 24) . DES, acting via the estrogen receptor, results in aberrant HOX gene expression.

Estrogens exert their effects by binding to estrogen receptors, which act as transcription factors (25 , 26) . There are two genes that encode estrogen receptors. Estrogen receptor {alpha} is known to regulate the differentiation and adult maintenance of reproductive tissues (27 , 28) . Estrogen-like agents that bind to the estrogen receptor are currently used to treat menopause, osteoporosis, cardiovascular disease, and breast cancer (29 , 30) . 17ß-Estradiol and DES both bind to the ligand binding domain (LBD) at the carboxyl terminus of the estrogen receptor. Ligand-dependent activation of transcription requires interaction with coactivators (31 , 32) . The crystal structure of the ER LBD bound to DES and other estrogens shows that different estrogens induce differential coactivator binding (33 , 34) . 17ß-Estradiol and DES likely have different effects on reproductive tract development because of different abilities to interact with coactivators necessary for proper Hox expression. This suggests that Hox gene expression is regulated by combined ER, coactivator, and estrogen action. DES likely interferes with the formation of the ER–coactivator complex necessary for proper tissue specific transcription. The present study provides evidence that the transcriptional regulation of Hox gene expression is altered by DES.

Alteration in Hox gene expression persists in the adult
The alteration in Hox gene expression described here persists well beyond the time of exposure to DES. This observation demonstrates that altered Hox gene expression may be a potential marker in the adult of the adverse developmental effects of in utero drug exposure. DES-related anomalies in women were not noted until those exposed in utero were young adults. Changes in the expression of Hox genes is a possible mechanism by which one could test for the ability of a drug to alter development or discern past exposure to agents that might alter developmental regulation.

Between 10 and 70% of exposed women demonstrated abnormalities of the reproductive tract (1) . Frequency of müllerian abnormalities is related to the gestational age at the time of exposure and the total dose of DES received. This variability is also likely due to differences in detection. An association between clear cell adenocarinoma of the vagina in women and in utero DES exposure has been clearly established, yet the mechanism by which DES leads to carcinogenesis is not understood (2) . Of those women exposed to DES in vitro, only ~1 per 1000 develop vaginal adenocarcinoma. Although vaginal developmental anomalies (vaginal adenosis) are a common finding in women exposed to DES, clear cell adenocarcinoma is rare. Factors other than DES are undoubtedly involved in the etiology of this tumor. The findings of this study suggest that altered development of the reproductive tract occurs via altered HOX gene expression. The resultant homeotic transformation of tissue identity, such as ectopic tissue in the vagina, may then be susceptible to carcinogenesis. Localization to the cervix may normally offer protection; exposure via the vagina to carcinogens may make vaginal adenosis prone to cancer formation. Hormonal carcinogenesis may be an indirect effect of homeotic transformation during development rather than a direct effect of DES.


   ACKNOWLEDGMENTS
 
Supported by a grant from the National Institute of Child Health and Human Development to H.T.


   FOOTNOTES
 
Received for publication May 27, 1999. Revised for publication January 12, 2000.


   REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 

  1. Noller, K. L., Fish, C. R. (1974) Diethylstilbestrol usage; its interesting past, important present, and questionable future. Med. Clin. N. Am. 58,739-810
  2. Herbst, A. L., Ulfelder, H., Poskanzer, D. C. (1971) Adenocarcinoma of the vagina. Association of maternal stilboestrol therapy with tumor appearance in young women. N. Engl. J. Med. 284,878-881
  3. Mably, T. A., Bjerke, D. L., Moore, R. W., Gendron Fitzpatrick, A., Peterson, R. E. (1992) In utero and lactational exposure of male rats to 2,3,7,8-tetra-chlorodibenso-p-dioxin. 3. Effects on spermatogenesis and reproductive capability. Toxicol. Appl. Pharmacol. 114,118-126[Medline]
  4. Walters, L. M., Rourke, A. W., Eroschenko, V. P. (1993) Purified methoxychlor stimulates the reproductive tract in immature female mice. Reprod. Toxicol. 7,599-606[Medline]
  5. Kaldas, R. S., Hughes, C. L. J. (1989) Reproductive and general metabolic effects on phytoestrogens in mammals. Reprod. Toxicol. 3,81-89[Medline]
  6. Taylor, H. S., Vanden Heuvel, G., Igarashi, P. (1997) A conserved hox axis in the mouse and human reproductive system: late establishment and persistent expression of the hoxa cluster genes. Biol. Reprod. 57,1338-1345[Abstract]
  7. Benson, G. V., Lim, H., Parai, B. C., Satoka, I., Dey, S. K., Maas, R. S. (1996) Mechanisms of reduced fertility in Hoxa-10 mutant mice: uterine homeosis and loss of maternal Hoxa-10 expression. Development 122,2687-2696[Abstract]
  8. Gendron, R. L., Paradise, H., Hsieh Li, H. M., Lee, D. W., Potter, S. S., Markoff, E. (1997) Abnormal uterine stromal and glandular function associated with maternal reproductive defects in Hoxa-11 null mice. Biol. Reprod. 56,1097-1105[Abstract]
  9. Hsieh Li, H. M., Witte, D. P., Weinstein, M., Branford, W., Li, H., Small, K., Potter, S. (1995) Hoxa11 structure, extensive antisense transcription, and function in male and female infertility. Development 121,1373-1385[Abstract]
  10. Satokata, I., Benson, G., Maas, R. (1995) Sexually dimorphic sterility phenotypes in Hoxa-10 deficient mice. Nature (London) 374,46-463
  11. Mortlock, D. P., Innis, J. W. (1997) Mutation of HOXA13 in hand-foot-genital syndrome. Nat. Genet. 15,179-180[Medline]
  12. Warot, X., Fromental Ramain, C., Fraulob, V., Chambon, P., Dolle, P. (1997) Gene dosage-dependent effects of the Hoxa-13 and Hoxd13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development 124,4781-4791[Abstract]
  13. Taylor, H. S., Arici, A., Olive, D., Igarashi, P. (1998) HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium. J. Clin. Invest. 101,1379-1384[Medline]
  14. Taylor, H. S., Igarashi, P., Olive, D., Arici, A. (1999) Sex steroids mediate HOXA11 expression in human peri-implantation endometrium. J. Clin. Endocr. Metab. 84,1129-1135[Abstract/Free Full Text]
  15. McLachlan, J., Newbold, R., Bullock, B. (1980) Long-term effects of the female mouse genital tract associated with prenatal exposure to diethylstilbestrol. Cancer Res 40,3988-3999[Abstract/Free Full Text]
  16. Nomura, T., Kanzaki, T. (1977) Induction of urogenital anomalies and some tumors in the progeny of mice receiving diethylstilbestrol during pregnancy. Cancer Res 37,1099-1104[Abstract/Free Full Text]
  17. Duboule, D. (1991) Pattern formation in the vertebrate limb. Curr. Opin. Genet. Dev. 1,211-216[Medline]
  18. Krumlauf, R. (1994) Hox genes in vertebrate development. Cell 78,191-201[Medline]
  19. DeCherney, A. H., Sholst, I., Naftolin, F. (1981) Structure and function of the fallopian tubes after exposure to diethylstilbestrol (DES) during gestation. Fertil. Steril. 36,741-745[Medline]
  20. Manzanares, M., Cordes, S., Kwan, C. T., Sham, M. H., Barsh, G. S., Krumlauf, R. (1997) Segmental regulation of Hoxb-3 by kriesler. Nature (London) 387,191-195[Medline]
  21. Sham, M. H. (1993) The zinc finger gene Krox20 regulates HoxB2 (hox2.8) during hindbrain segmentation. Cell 72,183-196[Medline]
  22. Marshall, H., Studer, M., Popperl, H., Aparicio, S., Kuroiwa, A., Brenner, S., Krumlauf, R. (1994) A conserved retinoic acid response element required for early expression of the homeobox gene Hoxb-1. Nature (London) 370,567-571[Medline]
  23. Boncinelli, E., Simeone, A., Acampora, D., Mavillo, F. (1991) Hox gene activation by retinoic acid. Trends Genet 7,329-334[Medline]
  24. Marshall, H., Nonchev, S., Sham, M. A., Muchamore, I., Lumsden, A., Krumlauf, R. (1992) Retinoic acid alters hindbrain Hox code and induces transformation of rhombomeres 2/3 into a 4/5 identity. Nature (London) 360,737-741[Medline]
  25. Tsai, M. J., O’Malley, B. W. (1994) Molecular Mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63,451-486[Medline]
  26. Beato, M., Herrlich, P., Schutz, G. (1995) Steroid hormone receptors: many actors in search of a plot. Cell 83,851-857[Medline]
  27. Korach, K. (1994) Insights from the study of animals lacking functional estrogen receptor. Science 266,1524-1527[Abstract/Free Full Text]
  28. Smith, E., Boyd, J., Frank, G., Takahashi, H., Cohen, R., Specker, B., Williams, T., Lubahn, D., Korach, K. (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331,1056-1061[Abstract/Free Full Text]
  29. Gradishar, W. J., Jordan, V. C. (1997) Clinical potential of new antiestrogens. J. Clin. Oncol. 15,840-852[Abstract/Free Full Text]
  30. Jordan, V. C. (1998) Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J. Natl. Cancer Inst. 90,967-971[Free Full Text]
  31. Glass, C. K., Rose, D. W., Rosenfeld, M. G. (1997) Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9,222-232[Medline]
  32. Horwitz, K. B., Jackson, T. A., Bain, D. L., Richer, J. K., Takimoto, G. S., Tung, L. (1996) Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10,1167-1177[Abstract]
  33. Tanenbaum, D. M., Wang, Y., Williams, S. P., Sigler, P. B. (1998) Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains. Proc. Natl. Acad. Sci. USA 95,5998-6003[Abstract/Free Full Text]
  34. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., Greene, G. L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95,927-937[Medline]



This article has been cited by other articles:


Home page
Hum ReprodHome page
B. Xu, D. Geerts, K. Qian, H. Zhang, and G. Zhu
Myeloid ecotropic viral integration site 1 (MEIS) 1 involvement in embryonic implantation
Hum. Reprod., June 1, 2008; 23(6): 1394 - 1406.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
D. Vitiello, R. Pinard, and H. S. Taylor
Gene Expression Profiling Reveals Putative HOXA10 Downstream Targets in the Periimplantation Mouse Uterus
Reproductive Sciences, May 1, 2008; 15(5): 529 - 535.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Martin, M. B. Taylor, G. Krikun, C. Lockwood, G. E. Akbas, and H. S. Taylor
Differential Cell-Specific Modulation of HOXA10 by Estrogen and Specificity Protein 1 Response Elements
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1920 - 1926.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
A. Suzuki, H. Urushitani, T. Sato, T. Kobayashi, H. Watanabe, Y. Ohta, and T. Iguchi
Gene Expression Change in the Mullerian Duct of the Mouse Fetus Exposed to Diethylstilbestrol In Utero
Experimental Biology and Medicine, April 1, 2007; 232(4): 503 - 514.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
J. H. Segars
Invited Comment: "Identification of a Sensitive Period for Developmental Programming That Increases Risk for Uterine Leiomyoma in Eker Rats"
Reproductive Sciences, February 1, 2007; 14(2): 99 - 100.
[PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
G. E. Akbas, X. Fei, and H. S. Taylor
Regulation of HOXA10 expression by phytoestrogens
Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E435 - E442.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
C. C. Smith and H. S. Taylor
Xenoestrogen exposure imprints expression of genes (Hoxa10) required for normal uterine development
FASEB J, January 1, 2007; 21(1): 239 - 246.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
S. DE ASSIS and L. HILAKIVI-CLARKE
Timing of Dietary Estrogenic Exposures and Breast Cancer Risk
Ann. N.Y. Acad. Sci., November 1, 2006; 1089(1): 14 - 35.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
C L Acerini and I A Hughes
Endocrine disrupting chemicals: a new and emerging public health problem?
Arch. Dis. Child., August 1, 2006; 91(8): 633 - 641.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. S. Daftary and H. S. Taylor
Endocrine Regulation of HOX Genes
Endocr. Rev., June 1, 2006; 27(4): 331 - 355.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. V. Henley and K. S. Korach
Endocrine-Disrupting Chemicals Use Distinct Mechanisms of Action to Modulate Endocrine System Function
Endocrinology, June 1, 2006; 147(6): s25 - s32.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. R. Newbold, E. Padilla-Banks, and W. N. Jefferson
Adverse Effects of the Model Environmental Estrogen Diethylstilbestrol Are Transmitted to Subsequent Generations
Endocrinology, June 1, 2006; 147(6): s11 - s17.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A.K. Bang, E. Carlsen, M. Holm, J.H. Petersen, N.E. Skakkebaek, and N. Jorgensen
A study of finger lengths, semen quality and sex hormones in 360 young men from the general Danish population
Hum. Reprod., November 1, 2005; 20(11): 3109 - 3113.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
H. Du, G. S. Daftary, S. I. Lalwani, and H. S. Taylor
Direct Regulation of HOXA10 by 1,25-(OH)2D3 in Human Myelomonocytic Cells and Human Endometrial Stromal Cells
Mol. Endocrinol., September 1, 2005; 19(9): 2222 - 2233.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Munoz-de-Toro, C. M. Markey, P. R. Wadia, E. H. Luque, B. S. Rubin, C. Sonnenschein, and A. M. Soto
Perinatal Exposure to Bisphenol-A Alters Peripubertal Mammary Gland Development in Mice
Endocrinology, September 1, 2005; 146(9): 4138 - 4147.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
X. Fei, H. Chung, and H. S. Taylor
Methoxychlor Disrupts Uterine Hoxa10 Gene Expression
Endocrinology, August 1, 2005; 146(8): 3445 - 3451.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. L. Sarno, H. J. Kliman, and H. S. Taylor
HOXA10, Pbx2, and Meis1 Protein Expression in the Human Endometrium: Formation of Multimeric Complexes on HOXA10 Target Genes
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 522 - 528.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
H. EUN KWON and H. S. TAYLOR
The Role of HOX Genes in Human Implantation
Ann. N.Y. Acad. Sci., December 1, 2004; 1034(1): 1 - 18.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
L. Carta and D. Sassoon
Wnt7a Is a Suppressor of Cell Death in the Female Reproductive Tract and Is Required for Postnatal and Estrogen-Mediated Growth
Biol Reprod, August 1, 2004; 71(2): 444 - 454.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. S. Daftary and H. S. Taylor
EMX2 Gene Expression in the Female Reproductive Tract and Aberrant Expression in the Endometrium of Patients with Endometriosis
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2390 - 2396.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
M. Mericskay, J. Kitajewski, and D. Sassoon
Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus
Development, May 1, 2004; 131(9): 2061 - 2072.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J.J. Buck, R.M. Williams, I.A. Hughes, and C.L. Acerini
In-utero androgen exposure and 2nd to 4th digit length ratio--comparisons between healthy controls and females with classical congenital adrenal hyperplasia
Hum. Reprod., May 1, 2003; 18(5): 976 - 979.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
S. LI, S. D. HURSTING, B. J. DAVIS, J. A. McLACHLAN, and J. C. BARRETT
Environmental Exposure, DNA Methylation, and Gene Regulation: Lessons from Diethylstilbesterol-Induced Cancers
Ann. N.Y. Acad. Sci., March 1, 2003; 983(1): 161 - 169.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
P. J. Troy, G. S. Daftary, C. N. Bagot, and H. S. Taylor
Transcriptional Repression of Peri-Implantation EMX2 Expression in Mammalian Reproduction by HOXA10
Mol. Cell. Biol., January 1, 2003; 23(1): 1 - 13.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Cermik, B. Selam, and H. S. Taylor
Regulation of HOXA-10 Expression by Testosterone in Vitro and in the Endometrium of Patients with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 238 - 243.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. R. Fielden, R. G. Halgren, C. J. Fong, C. Staub, L. Johnson, K. Chou, and T. R. Zacharewski
Gestational and Lactational Exposure of Male Mice to Diethylstilbestrol Causes Long-Term Effects on the Testis, Sperm Fertilizing Ability in Vitro, and Testicular Gene Expression
Endocrinology, August 1, 2002; 143(8): 3044 - 3059.
[Abstract] [Full Text] [PDF]